Physician profile
Moayed Ibrahim
NPI 1124400742
$1,058.31
in general payments reported to CMS, 2019-2025
22 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $384 · 2023: $33.32 · 2024: $213 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.78 |
| Education | $176.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $234.86 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $139.50 | 2022 | |
| Pfizer INC. | $109.92 | 2025 | |
| Daiichi Sankyo INC. | $107.22 | 2024-2025 | Enhertu |
| Btg International INC. | $97.65 | 2022 | |
| Aveo Pharmaceuticals, INC. | $75.00 | 2024-2025 | |
| Gilead Sciences, INC. | $22.14 | 2025 | Trodelvy |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Beigene USA, INC. | $21.67 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $21.52 | 2022 | |
| Tersera Therapeutics LLC | $20.00 | 2025 | Xermelo |
| Array Biopharma INC | $19.48 | 2025 | Lorbrena, Xalkori, Braftovi |
| Servier Pharmaceuticals LLC | $18.60 | 2023 | |
| Amgen INC. | $18.56 | 2025 | Imdelltra (Amg757) |
| Tempus Ai, INC | $18.51 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.16 | 2025 | |
| Lilly USA, LLC | $17.95 | 2024 | Jaypirca |
| Puma Biotechnology, INC. | $16.05 | 2024 | |
| Eisai INC. | $15.82 | 2024 | |
| Kite Pharma, INC. | $14.72 | 2023 | |
| Astellas Pharma US INC | $14.64 | 2024 | Padcev |
| Astrazeneca Pharmaceuticals Lp | $14.34 | 2025 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moayed Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.